Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospective, Observational, Multicentre, Single Group, Open-label Study to Confirm the Safety and Effectiveness of BIOCHROMADERM® Ink for the Reconstruction of the Nipple-areola Complex in Patients Undergoing Breast Reconstructive Surgery Following Mastectomy

NCT07261904 is registered in ClinicalTrials.gov with Laboratoires BIOTIC Phocea as lead sponsor.

NCT NCT07261904
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07261904 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prospective, Observational, Multicentre, Single Group, Open-label Study to Confirm the Safety and Effectiveness of BIOCHROMADERM® Ink for the Reconstruction of the Nipple-areola Complex in Patients Undergoing Breast Reconstructive Surgery Following Mastectomy
Lead sponsor
Laboratoires BIOTIC Phocea
Phase
Observational
Overall status
Recruiting
Start date
November 12, 2025
Completion date
June 12, 2027
Enrollment
115 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

reconstruction of the nipple-areola complex in patients undergoing breast reconstructive surgery following mastectomy